| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Renal Dialysis | 21 | 2024 | 889 | 3.710 |
Why?
|
| Blood Component Removal | 5 | 2025 | 35 | 2.570 |
Why?
|
| Plasma Exchange | 8 | 2025 | 89 | 2.390 |
Why?
|
| Kidney Failure, Chronic | 10 | 2022 | 915 | 1.780 |
Why?
|
| Hypocalcemia | 3 | 2020 | 38 | 1.390 |
Why?
|
| Calcinosis | 4 | 2014 | 193 | 1.370 |
Why?
|
| Kidney Transplantation | 6 | 2025 | 689 | 1.270 |
Why?
|
| Glomerulosclerosis, Focal Segmental | 2 | 2025 | 33 | 1.130 |
Why?
|
| Hematocrit | 2 | 2020 | 116 | 1.110 |
Why?
|
| Oxygen | 2 | 2021 | 582 | 1.080 |
Why?
|
| Acute Kidney Injury | 8 | 2025 | 704 | 1.020 |
Why?
|
| Child | 53 | 2025 | 25839 | 0.960 |
Why?
|
| Ectodermal Dysplasia | 1 | 2025 | 46 | 0.920 |
Why?
|
| Blood Pressure Monitoring, Ambulatory | 4 | 2022 | 53 | 0.900 |
Why?
|
| Nutrition Assessment | 4 | 2018 | 138 | 0.900 |
Why?
|
| Child Nutrition Disorders | 2 | 2018 | 77 | 0.870 |
Why?
|
| Phosphorus | 3 | 2014 | 61 | 0.870 |
Why?
|
| Adolescent | 37 | 2025 | 20599 | 0.860 |
Why?
|
| Fibroblast Growth Factors | 4 | 2022 | 162 | 0.850 |
Why?
|
| Citric Acid | 3 | 2018 | 38 | 0.840 |
Why?
|
| Oximetry | 2 | 2021 | 179 | 0.790 |
Why?
|
| Protein-Energy Malnutrition | 3 | 2017 | 76 | 0.780 |
Why?
|
| Renal Insufficiency, Chronic | 9 | 2024 | 807 | 0.730 |
Why?
|
| Brain Chemistry | 1 | 2021 | 125 | 0.720 |
Why?
|
| Multiple Organ Failure | 2 | 2024 | 144 | 0.700 |
Why?
|
| Registries | 2 | 2025 | 1577 | 0.690 |
Why?
|
| Blood Volume | 2 | 2021 | 83 | 0.680 |
Why?
|
| Liver Transplantation | 4 | 2025 | 1128 | 0.670 |
Why?
|
| Blood | 1 | 2020 | 109 | 0.660 |
Why?
|
| Young Adult | 19 | 2025 | 9916 | 0.660 |
Why?
|
| Veins | 1 | 2020 | 108 | 0.650 |
Why?
|
| Nutritional Status | 6 | 2024 | 325 | 0.640 |
Why?
|
| Hypertrophy, Left Ventricular | 2 | 2021 | 114 | 0.630 |
Why?
|
| Hypertension | 5 | 2022 | 1396 | 0.610 |
Why?
|
| Arterial Pressure | 1 | 2019 | 124 | 0.580 |
Why?
|
| Vascular Stiffness | 1 | 2019 | 80 | 0.570 |
Why?
|
| Child, Hospitalized | 1 | 2018 | 76 | 0.570 |
Why?
|
| Hyperglycemic Hyperosmolar Nonketotic Coma | 1 | 2017 | 9 | 0.570 |
Why?
|
| Plethysmography | 1 | 2017 | 35 | 0.560 |
Why?
|
| Male | 45 | 2025 | 66045 | 0.560 |
Why?
|
| Electric Impedance | 1 | 2017 | 68 | 0.550 |
Why?
|
| Humans | 66 | 2025 | 134059 | 0.520 |
Why?
|
| Heart | 1 | 2021 | 749 | 0.520 |
Why?
|
| Kidney Diseases | 1 | 2021 | 505 | 0.520 |
Why?
|
| Female | 44 | 2025 | 71845 | 0.500 |
Why?
|
| Child, Preschool | 27 | 2025 | 14835 | 0.490 |
Why?
|
| Thrombocytopenia | 1 | 2017 | 237 | 0.490 |
Why?
|
| Dietary Proteins | 2 | 2018 | 252 | 0.480 |
Why?
|
| Renal Replacement Therapy | 5 | 2024 | 157 | 0.470 |
Why?
|
| Calcium | 3 | 2017 | 1148 | 0.470 |
Why?
|
| Renal Insufficiency | 3 | 2024 | 254 | 0.460 |
Why?
|
| Body Composition | 1 | 2017 | 561 | 0.450 |
Why?
|
| Glomerular Filtration Rate | 4 | 2024 | 549 | 0.450 |
Why?
|
| Hemoglobins | 2 | 2017 | 322 | 0.440 |
Why?
|
| Peritoneal Dialysis | 3 | 2019 | 132 | 0.440 |
Why?
|
| Coronary Artery Disease | 2 | 2011 | 894 | 0.410 |
Why?
|
| Blood Urea Nitrogen | 1 | 2012 | 77 | 0.400 |
Why?
|
| Glucose | 1 | 2017 | 927 | 0.400 |
Why?
|
| Infant | 24 | 2025 | 13199 | 0.400 |
Why?
|
| Cardiovascular Diseases | 2 | 2016 | 2090 | 0.390 |
Why?
|
| Retrospective Studies | 23 | 2025 | 17517 | 0.390 |
Why?
|
| Pediatrics | 1 | 2020 | 1215 | 0.350 |
Why?
|
| Kidney | 6 | 2023 | 1421 | 0.350 |
Why?
|
| Glomerulonephritis, IGA | 1 | 2009 | 17 | 0.330 |
Why?
|
| Coronary Disease | 1 | 2013 | 721 | 0.310 |
Why?
|
| Risk Assessment | 2 | 2018 | 3729 | 0.310 |
Why?
|
| Critical Illness | 5 | 2025 | 629 | 0.300 |
Why?
|
| Thrombotic Microangiopathies | 2 | 2020 | 53 | 0.300 |
Why?
|
| Anticoagulants | 3 | 2018 | 614 | 0.300 |
Why?
|
| Cardiomyopathies | 1 | 2013 | 518 | 0.290 |
Why?
|
| Nutritional Support | 2 | 2019 | 57 | 0.290 |
Why?
|
| Drug Utilization Review | 1 | 2007 | 33 | 0.280 |
Why?
|
| Models, Biological | 1 | 2012 | 1540 | 0.270 |
Why?
|
| Age Factors | 4 | 2021 | 2997 | 0.260 |
Why?
|
| Stroke Volume | 2 | 2021 | 535 | 0.260 |
Why?
|
| Hemorrhage | 1 | 2009 | 512 | 0.250 |
Why?
|
| Vitamin D Deficiency | 2 | 2024 | 76 | 0.250 |
Why?
|
| Lung Diseases | 1 | 2009 | 403 | 0.250 |
Why?
|
| Community-Acquired Infections | 1 | 2007 | 247 | 0.240 |
Why?
|
| Treatment Outcome | 9 | 2025 | 13048 | 0.240 |
Why?
|
| Leukapheresis | 1 | 2025 | 14 | 0.230 |
Why?
|
| Microfluidics | 1 | 2025 | 28 | 0.230 |
Why?
|
| Graft Survival | 3 | 2022 | 557 | 0.230 |
Why?
|
| Water-Electrolyte Balance | 1 | 2025 | 83 | 0.230 |
Why?
|
| Anemia | 3 | 2020 | 349 | 0.220 |
Why?
|
| Bacillus cereus | 1 | 2004 | 11 | 0.220 |
Why?
|
| Bone Diseases, Metabolic | 1 | 2024 | 59 | 0.220 |
Why?
|
| Pneumonia | 1 | 2007 | 343 | 0.220 |
Why?
|
| Cystatin C | 1 | 2024 | 66 | 0.210 |
Why?
|
| Time Factors | 6 | 2021 | 6604 | 0.210 |
Why?
|
| Tomography, X-Ray Computed | 4 | 2014 | 2196 | 0.210 |
Why?
|
| Hemophilia A | 1 | 2004 | 26 | 0.210 |
Why?
|
| Diagnostic Errors | 1 | 2007 | 347 | 0.210 |
Why?
|
| Gram-Positive Bacterial Infections | 1 | 2004 | 79 | 0.210 |
Why?
|
| Adult | 8 | 2025 | 31961 | 0.210 |
Why?
|
| Vitamin D | 1 | 2024 | 178 | 0.200 |
Why?
|
| Catheterization, Central Venous | 1 | 2004 | 137 | 0.200 |
Why?
|
| Creatinine | 2 | 2024 | 429 | 0.190 |
Why?
|
| Fasciitis, Necrotizing | 1 | 2022 | 29 | 0.190 |
Why?
|
| Malnutrition | 2 | 2019 | 218 | 0.190 |
Why?
|
| Myelitis | 1 | 2022 | 15 | 0.190 |
Why?
|
| Inflammation | 1 | 2009 | 1593 | 0.180 |
Why?
|
| Hypoxia, Brain | 1 | 2021 | 35 | 0.180 |
Why?
|
| Body Mass Index | 2 | 2018 | 1717 | 0.180 |
Why?
|
| Arteriovenous Fistula | 1 | 2022 | 56 | 0.180 |
Why?
|
| Enterovirus | 1 | 2022 | 52 | 0.180 |
Why?
|
| Water-Electrolyte Imbalance | 1 | 2022 | 79 | 0.180 |
Why?
|
| Recurrence | 1 | 2025 | 1472 | 0.180 |
Why?
|
| Enterovirus Infections | 1 | 2022 | 49 | 0.180 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 2 | 2021 | 1187 | 0.180 |
Why?
|
| Injection Site Reaction | 1 | 2021 | 7 | 0.180 |
Why?
|
| Arteriovenous Shunt, Surgical | 1 | 2022 | 95 | 0.180 |
Why?
|
| Interleukin-8 | 2 | 2014 | 221 | 0.180 |
Why?
|
| White Coat Hypertension | 1 | 2021 | 11 | 0.180 |
Why?
|
| Myositis | 1 | 2022 | 104 | 0.170 |
Why?
|
| BK Virus | 1 | 2021 | 61 | 0.170 |
Why?
|
| Plasmapheresis | 1 | 2020 | 35 | 0.170 |
Why?
|
| Chronic Kidney Disease-Mineral and Bone Disorder | 2 | 2011 | 13 | 0.170 |
Why?
|
| Cystitis | 1 | 2021 | 51 | 0.170 |
Why?
|
| Hemodynamics | 2 | 2022 | 872 | 0.170 |
Why?
|
| Polyomavirus Infections | 1 | 2021 | 91 | 0.170 |
Why?
|
| Blood Gas Analysis | 1 | 2020 | 85 | 0.170 |
Why?
|
| Tumor Virus Infections | 1 | 2021 | 141 | 0.170 |
Why?
|
| Accreditation | 1 | 2020 | 93 | 0.170 |
Why?
|
| Hypotension | 1 | 2022 | 190 | 0.160 |
Why?
|
| Prevalence | 3 | 2024 | 2683 | 0.160 |
Why?
|
| Calcimimetic Agents | 1 | 2019 | 5 | 0.160 |
Why?
|
| Cross-Sectional Studies | 4 | 2020 | 3753 | 0.160 |
Why?
|
| Vesico-Ureteral Reflux | 2 | 2020 | 82 | 0.160 |
Why?
|
| Rituximab | 1 | 2021 | 164 | 0.160 |
Why?
|
| Hyperparathyroidism, Secondary | 1 | 2019 | 17 | 0.160 |
Why?
|
| Interleukin-6 | 2 | 2014 | 451 | 0.160 |
Why?
|
| Anaphylaxis | 1 | 2021 | 86 | 0.160 |
Why?
|
| Immunologic Factors | 1 | 2021 | 184 | 0.160 |
Why?
|
| Heart Failure | 2 | 2023 | 2427 | 0.160 |
Why?
|
| Infant Formula | 1 | 2020 | 100 | 0.160 |
Why?
|
| Education, Medical | 1 | 2023 | 302 | 0.160 |
Why?
|
| Neutropenia | 1 | 2021 | 204 | 0.160 |
Why?
|
| Protein Deficiency | 1 | 2019 | 20 | 0.150 |
Why?
|
| C-Reactive Protein | 2 | 2014 | 471 | 0.150 |
Why?
|
| Pulse Wave Analysis | 1 | 2019 | 51 | 0.150 |
Why?
|
| Genu Valgum | 1 | 2018 | 3 | 0.150 |
Why?
|
| Serum Albumin, Human | 1 | 2018 | 8 | 0.150 |
Why?
|
| Hypercalciuria | 1 | 2018 | 8 | 0.150 |
Why?
|
| Hemofiltration | 1 | 2018 | 11 | 0.150 |
Why?
|
| Familial Hypophosphatemic Rickets | 1 | 2018 | 7 | 0.150 |
Why?
|
| Urogenital Abnormalities | 2 | 2020 | 160 | 0.150 |
Why?
|
| Blood Group Incompatibility | 1 | 2018 | 27 | 0.150 |
Why?
|
| Prospective Studies | 5 | 2024 | 6602 | 0.150 |
Why?
|
| ABO Blood-Group System | 1 | 2018 | 68 | 0.150 |
Why?
|
| Extracorporeal Circulation | 1 | 2018 | 55 | 0.140 |
Why?
|
| Hypersensitivity | 1 | 2020 | 194 | 0.140 |
Why?
|
| Cerebrovascular Circulation | 1 | 2021 | 474 | 0.140 |
Why?
|
| Ventricular Dysfunction, Left | 1 | 2021 | 382 | 0.140 |
Why?
|
| Anthropometry | 1 | 2018 | 205 | 0.140 |
Why?
|
| Liver Failure | 1 | 2018 | 91 | 0.140 |
Why?
|
| Cohort Studies | 5 | 2024 | 5206 | 0.140 |
Why?
|
| Darbepoetin alfa | 1 | 2017 | 14 | 0.140 |
Why?
|
| Ventricular Function, Left | 1 | 2021 | 545 | 0.140 |
Why?
|
| Arteries | 1 | 2019 | 230 | 0.140 |
Why?
|
| Risk Factors | 5 | 2021 | 11163 | 0.140 |
Why?
|
| Statistics, Nonparametric | 2 | 2016 | 454 | 0.140 |
Why?
|
| Milk, Human | 1 | 2020 | 311 | 0.130 |
Why?
|
| Hematinics | 1 | 2017 | 60 | 0.130 |
Why?
|
| Acute-On-Chronic Liver Failure | 1 | 2018 | 80 | 0.130 |
Why?
|
| Infant, Newborn | 4 | 2024 | 8607 | 0.130 |
Why?
|
| Myocardium | 1 | 2021 | 1046 | 0.130 |
Why?
|
| Liver Failure, Acute | 1 | 2017 | 96 | 0.130 |
Why?
|
| Appetite | 1 | 2016 | 35 | 0.120 |
Why?
|
| Atypical Hemolytic Uremic Syndrome | 1 | 2015 | 9 | 0.120 |
Why?
|
| Fever of Unknown Origin | 1 | 1996 | 45 | 0.120 |
Why?
|
| Anti-Bacterial Agents | 1 | 2007 | 2573 | 0.120 |
Why?
|
| Echocardiography | 1 | 2021 | 1131 | 0.120 |
Why?
|
| Predictive Value of Tests | 3 | 2021 | 2301 | 0.120 |
Why?
|
| Ultrasonography, Doppler | 1 | 2016 | 198 | 0.120 |
Why?
|
| Drug Administration Schedule | 3 | 2017 | 756 | 0.120 |
Why?
|
| Blood Pressure | 3 | 2022 | 1420 | 0.120 |
Why?
|
| Biomarkers | 4 | 2020 | 3432 | 0.120 |
Why?
|
| Education, Medical, Graduate | 1 | 2020 | 560 | 0.120 |
Why?
|
| Heart-Assist Devices | 1 | 2023 | 1094 | 0.110 |
Why?
|
| Intensive Care Units | 1 | 2018 | 538 | 0.110 |
Why?
|
| Longitudinal Studies | 2 | 2021 | 1504 | 0.110 |
Why?
|
| Pilot Projects | 1 | 2018 | 1492 | 0.110 |
Why?
|
| Chronic Disease | 1 | 2018 | 1255 | 0.110 |
Why?
|
| Developing Countries | 1 | 1996 | 289 | 0.110 |
Why?
|
| Nervous System Diseases | 1 | 2018 | 412 | 0.100 |
Why?
|
| United States | 3 | 2025 | 11748 | 0.100 |
Why?
|
| Heart Rate | 1 | 2016 | 600 | 0.100 |
Why?
|
| Intensive Care Units, Pediatric | 3 | 2025 | 485 | 0.100 |
Why?
|
| Hospitalization | 4 | 2022 | 1901 | 0.100 |
Why?
|
| Length of Stay | 1 | 2018 | 1389 | 0.100 |
Why?
|
| California | 1 | 2012 | 144 | 0.100 |
Why?
|
| Urinary Tract Infections | 1 | 1996 | 307 | 0.090 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2013 | 867 | 0.090 |
Why?
|
| Texas | 3 | 2021 | 3715 | 0.090 |
Why?
|
| DNA Copy Number Variations | 1 | 2016 | 1019 | 0.090 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2015 | 555 | 0.090 |
Why?
|
| Regression Analysis | 1 | 2012 | 826 | 0.090 |
Why?
|
| Hyperuricemia | 1 | 2011 | 42 | 0.090 |
Why?
|
| Uric Acid | 1 | 2011 | 110 | 0.080 |
Why?
|
| Mass Screening | 1 | 1996 | 840 | 0.080 |
Why?
|
| Serum Albumin | 1 | 2009 | 117 | 0.080 |
Why?
|
| Methylprednisolone | 1 | 2009 | 102 | 0.080 |
Why?
|
| Genetic Predisposition to Disease | 2 | 2018 | 3487 | 0.080 |
Why?
|
| Pulmonary Alveoli | 1 | 2009 | 142 | 0.080 |
Why?
|
| Cost Savings | 1 | 2008 | 75 | 0.070 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2011 | 616 | 0.070 |
Why?
|
| Radiography, Thoracic | 1 | 2007 | 152 | 0.070 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2009 | 316 | 0.070 |
Why?
|
| Disease Progression | 1 | 2013 | 2264 | 0.070 |
Why?
|
| Child Nutritional Physiological Phenomena | 1 | 2008 | 174 | 0.070 |
Why?
|
| Cholesterol | 1 | 2009 | 574 | 0.070 |
Why?
|
| Parenteral Nutrition | 1 | 2008 | 199 | 0.060 |
Why?
|
| Graft Rejection | 2 | 2022 | 629 | 0.060 |
Why?
|
| Biopsy | 1 | 2009 | 1303 | 0.060 |
Why?
|
| Obesity | 1 | 2017 | 2446 | 0.060 |
Why?
|
| Reproducibility of Results | 1 | 2012 | 3043 | 0.060 |
Why?
|
| Follow-Up Studies | 3 | 2021 | 5476 | 0.060 |
Why?
|
| Quality Indicators, Health Care | 1 | 2007 | 231 | 0.060 |
Why?
|
| Health Care Costs | 1 | 2008 | 407 | 0.060 |
Why?
|
| Leukocytosis | 1 | 2025 | 48 | 0.060 |
Why?
|
| Leukocyte Count | 1 | 2025 | 258 | 0.060 |
Why?
|
| Cell Separation | 1 | 2025 | 234 | 0.060 |
Why?
|
| Organ Dysfunction Scores | 1 | 2024 | 51 | 0.050 |
Why?
|
| Quality of Life | 3 | 2020 | 2157 | 0.050 |
Why?
|
| Leukocytes | 1 | 2025 | 223 | 0.050 |
Why?
|
| Nitrogen | 1 | 2024 | 148 | 0.050 |
Why?
|
| Catheters, Indwelling | 1 | 2004 | 157 | 0.050 |
Why?
|
| Sodium Potassium Chloride Symporter Inhibitors | 1 | 2022 | 32 | 0.050 |
Why?
|
| Chlorides | 1 | 2022 | 108 | 0.050 |
Why?
|
| Proteins | 1 | 2008 | 1098 | 0.050 |
Why?
|
| Fractures, Bone | 1 | 2024 | 212 | 0.050 |
Why?
|
| Minerals | 1 | 2022 | 59 | 0.050 |
Why?
|
| Ferric Compounds | 1 | 2022 | 41 | 0.050 |
Why?
|
| Lung | 1 | 2009 | 1575 | 0.050 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2025 | 1310 | 0.050 |
Why?
|
| Phosphates | 1 | 2022 | 121 | 0.050 |
Why?
|
| Diagnosis, Differential | 2 | 2018 | 1977 | 0.050 |
Why?
|
| Diuretics | 1 | 2022 | 169 | 0.050 |
Why?
|
| Living Donors | 1 | 2022 | 118 | 0.050 |
Why?
|
| Leukoencephalopathy, Progressive Multifocal | 1 | 2021 | 18 | 0.040 |
Why?
|
| Long Term Adverse Effects | 1 | 2021 | 12 | 0.040 |
Why?
|
| Sodium | 1 | 2022 | 309 | 0.040 |
Why?
|
| Protective Factors | 1 | 2021 | 92 | 0.040 |
Why?
|
| Lymphocyte Count | 1 | 2021 | 125 | 0.040 |
Why?
|
| Agammaglobulinemia | 1 | 2021 | 43 | 0.040 |
Why?
|
| Catheterization | 1 | 2022 | 239 | 0.040 |
Why?
|
| Autoimmune Diseases of the Nervous System | 1 | 2021 | 36 | 0.040 |
Why?
|
| Nephrotic Syndrome | 1 | 2021 | 52 | 0.040 |
Why?
|
| Transplant Recipients | 1 | 2022 | 227 | 0.040 |
Why?
|
| Transplantation, Homologous | 1 | 2022 | 690 | 0.040 |
Why?
|
| Purpura, Thrombocytopenic, Idiopathic | 1 | 2021 | 50 | 0.040 |
Why?
|
| Practice Guidelines as Topic | 1 | 2007 | 1339 | 0.040 |
Why?
|
| Uganda | 1 | 2020 | 89 | 0.040 |
Why?
|
| Immunoglobulins, Intravenous | 1 | 2021 | 148 | 0.040 |
Why?
|
| Encephalitis | 1 | 2021 | 121 | 0.040 |
Why?
|
| Iron | 1 | 2022 | 305 | 0.040 |
Why?
|
| Sodium-Phosphate Cotransporter Proteins, Type IIc | 1 | 2018 | 3 | 0.040 |
Why?
|
| Tissue Donors | 1 | 2022 | 523 | 0.040 |
Why?
|
| Teaching Rounds | 1 | 2018 | 30 | 0.040 |
Why?
|
| Preoperative Period | 1 | 2018 | 93 | 0.040 |
Why?
|
| Rehabilitation | 1 | 2018 | 24 | 0.040 |
Why?
|
| Rats | 1 | 2025 | 3890 | 0.040 |
Why?
|
| Hospitals | 1 | 2021 | 437 | 0.040 |
Why?
|
| Lupus Erythematosus, Systemic | 1 | 2021 | 213 | 0.040 |
Why?
|
| Health Status Disparities | 1 | 2021 | 249 | 0.040 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2021 | 1145 | 0.040 |
Why?
|
| B-Lymphocytes | 1 | 2021 | 549 | 0.040 |
Why?
|
| Immune System Diseases | 1 | 2018 | 50 | 0.030 |
Why?
|
| Lymphoma | 1 | 2021 | 335 | 0.030 |
Why?
|
| Severity of Illness Index | 2 | 2021 | 3104 | 0.030 |
Why?
|
| Odds Ratio | 1 | 2021 | 1338 | 0.030 |
Why?
|
| Clinical Protocols | 1 | 2018 | 245 | 0.030 |
Why?
|
| Mexico | 1 | 2017 | 190 | 0.030 |
Why?
|
| Multiple Sclerosis | 1 | 2021 | 394 | 0.030 |
Why?
|
| Proportional Hazards Models | 1 | 2021 | 1488 | 0.030 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2022 | 1217 | 0.030 |
Why?
|
| PAX2 Transcription Factor | 1 | 2016 | 27 | 0.030 |
Why?
|
| Hepatocyte Nuclear Factor 1-beta | 1 | 2016 | 30 | 0.030 |
Why?
|
| Tertiary Care Centers | 1 | 2018 | 268 | 0.030 |
Why?
|
| Protein Tyrosine Phosphatases | 1 | 2016 | 78 | 0.030 |
Why?
|
| Europe | 1 | 2017 | 382 | 0.030 |
Why?
|
| DNA Mutational Analysis | 1 | 2018 | 840 | 0.030 |
Why?
|
| Aged, 80 and over | 1 | 2007 | 7205 | 0.030 |
Why?
|
| Logistic Models | 1 | 2021 | 1909 | 0.030 |
Why?
|
| Pandemics | 1 | 2023 | 1190 | 0.030 |
Why?
|
| India | 1 | 1996 | 239 | 0.030 |
Why?
|
| Drug Therapy, Combination | 1 | 2018 | 1199 | 0.030 |
Why?
|
| Combined Modality Therapy | 1 | 2018 | 1310 | 0.030 |
Why?
|
| Patient Care Team | 1 | 2018 | 573 | 0.030 |
Why?
|
| Forkhead Transcription Factors | 1 | 2016 | 389 | 0.030 |
Why?
|
| Immunosuppressive Agents | 1 | 2018 | 703 | 0.030 |
Why?
|
| Multivariate Analysis | 1 | 2017 | 1492 | 0.030 |
Why?
|
| Survival Analysis | 1 | 2017 | 1598 | 0.030 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2016 | 592 | 0.030 |
Why?
|
| Double-Blind Method | 1 | 2017 | 1664 | 0.030 |
Why?
|
| Surveys and Questionnaires | 1 | 2023 | 3999 | 0.030 |
Why?
|
| Pedigree | 1 | 2016 | 1698 | 0.020 |
Why?
|
| Quality Improvement | 1 | 2018 | 700 | 0.020 |
Why?
|
| Hospital Mortality | 1 | 2017 | 1095 | 0.020 |
Why?
|
| Repressor Proteins | 1 | 2016 | 871 | 0.020 |
Why?
|
| Nuclear Proteins | 1 | 2016 | 1343 | 0.020 |
Why?
|
| Linear Models | 1 | 2011 | 723 | 0.020 |
Why?
|
| Aged | 1 | 2007 | 21753 | 0.020 |
Why?
|
| Prognosis | 1 | 2018 | 5084 | 0.020 |
Why?
|
| Up-Regulation | 1 | 2011 | 914 | 0.020 |
Why?
|
| Blood Pressure Determination | 1 | 2008 | 115 | 0.020 |
Why?
|
| Probability | 1 | 2008 | 335 | 0.020 |
Why?
|
| Antihypertensive Agents | 1 | 2011 | 409 | 0.020 |
Why?
|
| Middle Aged | 1 | 2007 | 29399 | 0.020 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2016 | 2934 | 0.020 |
Why?
|
| Body Weight | 1 | 2011 | 1041 | 0.020 |
Why?
|
| Postoperative Complications | 1 | 2018 | 3177 | 0.020 |
Why?
|
| Cost-Benefit Analysis | 1 | 2008 | 563 | 0.020 |
Why?
|
| Mutation | 1 | 2018 | 6304 | 0.010 |
Why?
|
| Hospitals, Pediatric | 1 | 2008 | 791 | 0.010 |
Why?
|
| Animals | 1 | 2025 | 36539 | 0.010 |
Why?
|